Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zovaglutide in Hepatic Impairment
NCT07916194Phase 1Not yet recruiting
- Sponsor
- QL Biopharm
- Start
- Nov 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of zovaglutide in obesity (3 arms), sponsored by QL Biopharm. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Infinity at Day 36, Maximum Concentration at Day 36 and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
zovaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07916194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07916194.